Lexaria Bioscience (NASDAQ:LEXX) Upgraded to Hold at Wall Street Zen

Lexaria Bioscience (NASDAQ:LEXXGet Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lexaria Bioscience in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lexaria Bioscience presently has an average rating of “Hold” and a consensus target price of $4.00.

Check Out Our Latest Report on Lexaria Bioscience

Lexaria Bioscience Trading Down 2.2%

Shares of Lexaria Bioscience stock opened at $1.10 on Friday. The stock’s fifty day simple moving average is $1.02 and its 200 day simple moving average is $0.98. The company has a market capitalization of $24.34 million, a PE ratio of -1.63 and a beta of 0.71. Lexaria Bioscience has a 12 month low of $0.77 and a 12 month high of $2.85.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lexaria Bioscience stock. Virtu Financial LLC acquired a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXXFree Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.13% of Lexaria Bioscience as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

(Get Free Report)

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.

Read More

Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.